1 / 17

Genetics and Genomics in Clinical Medicine

Genetics and Genomics in Clinical Medicine. Raju Kucherlapati, Ph.D. Harvard Medical School Partners Healthcare. Healthcare Issues. Healthcare costs are rising rapidly Costs of drug development at all time high Estimated cost of a new drug 800 MM Drugs are not effective in all patients

manchu
Download Presentation

Genetics and Genomics in Clinical Medicine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Genetics and Genomics in Clinical Medicine Raju Kucherlapati, Ph.D. Harvard Medical School Partners Healthcare

  2. Healthcare Issues • Healthcare costs are rising rapidly • Costs of drug development at all time high • Estimated cost of a new drug 800 MM • Drugs are not effective in all patients • Some cancer drugs are effective in less than 20% of patients • Drug related adverse events are a major cause of ER visits • Even when drugs are effective severe adverse reactions can cause major problems • GENETICS AND GENOMICS CAN HELP

  3. National Thought Leaders on Personalized Medicine “I believe we are moving into a remarkable and powerful new era in medicine and particularly in prescription drugs. I’d refer to it as an era of personalized medicine.” Michael Leavitt, Secretary HHS January 18, 2005

  4. What is Personalized Medicine? • The right drug or treatment, at the right time, for the right patient, at the right cost everytime • Personalized medicine requires genetic or other type of testing • How fast the test results are available becomes critical

  5. Future of Medical Care • A revolution in medical practice and care has to take place • Personalized Medicine is a part of this revolution • Some would consider the notion of Personalized Medicine to be similar to many earlier disruptive technologies such as color television and personal computers • Implementation of Personalized Medicine would require changes in many paradigms that include • More discoveries • Effectiveness • Support of Regulatory agencies • Positive cost/benefit ratio • Rapid test results • Physician and Public Education • Effective IT support to manage and interpret results

  6. Discoveries are becoming more rapid August 2007 Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research et al

  7. Effectiveness • Effectiveness can be measured by clinical data • Retrospective studies • Prospective clinical trials • Examples of a prospective clinical trails • For new drugs – Herceptin, Gleevec • For approved drugs - Warfarin

  8. Genetics of Warfarin dosing • More than 20 million prescriptions of Warfarin every year and 2 million new patients/year are prescribed Warfarin. It is the most effective oral anticoagulant drug • Warfarin anticoagulation is prescribed to achieve a target INR. Excessive dosing precipitates hemorrhage. Inadequate dosing predisposes to stroke and pulmonary embolism. Dosing nomograms work poorly. Trial and error predominates. • CYP 2C9 VKORC1 • Genotype Dose Haplotype Dose • *1/*1 7.2 mg A/A 2.7 mg • *1/*2 4.1 mg A/B 4.9 mg • *1/*3 • *2/*2 1.4 mg B/B 6.2 mg • *2/*3 • *3/*3 • We are now conducting a clinical trial to test the hypothesis

  9. PERSONAL DOSEIn Milestone, FDA PushesGenetic Tests Tied to Drug Agency Seeks to TameRisks of Blood Thinner;Some Doctors Protest By ANNA WILDE MATHEWSAugust 16, 2007; Page A1 Regulatory Activity

  10. FDA Approves Label Change for Warfarin FDA Approves Genetic Testing Labeling For Blood-thinning DrugAugust 18, 2007 "Today's approved labeling change is one step in our commitment to personalized medicine. By using modern science to get the right drug in the right dose for the right patient, FDA will further enhance the safety and effectiveness of the medicines Americans depend on," Andrew C. von Eschenbach, M.D. Commissioner of FDA

  11. Cost/Benefit Analysis for Warfarin testing “We estimate that formally integrating genetic testing into routine warfarin therapy could allow American warfarin users to avoid 85,000 serious bleeding events and 17,000 strokes annually. We estimate the reduced health care spending from integrating genetic testing into warfarin therapy to be $1.1 billion annually, with a range of about $100 million to $2 billion.” Andrew McWilliam, Randall Lutter and Clark Nardinelli Office of Policy and Planning at the FDA AEI-BROOKINGS JOINT CENTER FOR REGULATORY STUDIES November 2006

  12. Time to Getting Test Results • For Warfarin testing turn around times are 7-10 days • Too late for clinical dosing decisions • Need to have answers within 24 hours, preferably a few hours • Ideal situation is POC diagnostic or a local lab that provides results fast • Need to get the result into the electronic medical record • Need to provide a dosing recommendation • We now provide Warfarin test results within 24 hours

  13. Genetic data in EMR

  14. Test Results in EMR

  15. First Genetics Based Clinical Decision Support Rule

  16. The Ultimate Goal Clinical data Genetic variation Genetic expression Personalized Healthcare Megabytes – Gigabytes of Data Per Patient The patient has disease X, subclass Y, which will likely respond to drug Z Proteomic expression

More Related